JP6896715B2 - セピアプテリン還元酵素としてのヘテロアリール誘導体 - Google Patents

セピアプテリン還元酵素としてのヘテロアリール誘導体 Download PDF

Info

Publication number
JP6896715B2
JP6896715B2 JP2018517345A JP2018517345A JP6896715B2 JP 6896715 B2 JP6896715 B2 JP 6896715B2 JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018517345 A JP2018517345 A JP 2018517345A JP 6896715 B2 JP6896715 B2 JP 6896715B2
Authority
JP
Japan
Prior art keywords
mmol
alkylene
methyl
solution
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018517345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529739A5 (enExample
JP2018529739A (ja
Inventor
テッベ，マーク，ジョセフ
アットン，ホリー，ヴィクトリア
アヴェリー，クレイグ
ブロミッジ，スティーブン，マーク
ケリー，マーク
コテイ，アドリアン，コテイ
モンク，ナサニエル，ジェイ
メニコーニ，ミルコ
リッジル，マーク，ペーター
タイ，ヘザー
サイヤ，エディーン
ジョンソン，カイ，ペーター
ゴルスカ，カタジーナ，イレナ
ペン，ハイルオ
マッコール，ジョン，ミカエル
Original Assignee
マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング
マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング, マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング filed Critical マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング
Publication of JP2018529739A publication Critical patent/JP2018529739A/ja
Publication of JP2018529739A5 publication Critical patent/JP2018529739A5/ja
Application granted granted Critical
Publication of JP6896715B2 publication Critical patent/JP6896715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018517345A 2015-09-30 2016-09-30 セピアプテリン還元酵素としてのヘテロアリール誘導体 Active JP6896715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235191P 2015-09-30 2015-09-30
US62/235,191 2015-09-30
PCT/US2016/054657 WO2017059191A1 (en) 2015-09-30 2016-09-30 Heteroaryl derivatives as sepiapterin reductase inhibitors

Publications (3)

Publication Number Publication Date
JP2018529739A JP2018529739A (ja) 2018-10-11
JP2018529739A5 JP2018529739A5 (enExample) 2019-11-14
JP6896715B2 true JP6896715B2 (ja) 2021-06-30

Family

ID=57133442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517345A Active JP6896715B2 (ja) 2015-09-30 2016-09-30 セピアプテリン還元酵素としてのヘテロアリール誘導体

Country Status (7)

Country Link
US (1) US9963462B2 (enExample)
EP (1) EP3356345B1 (enExample)
JP (1) JP6896715B2 (enExample)
CA (1) CA3038280A1 (enExample)
DK (1) DK3356345T3 (enExample)
ES (1) ES2969565T3 (enExample)
WO (1) WO2017059191A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN107312011A (zh) * 2017-06-29 2017-11-03 上海药明康德新药开发有限公司 外消旋‑7‑叔丁氧基羰基‑1‑氧亚基‑2,7‑二氮杂螺壬烷‑4‑羧酸的合成方法
CN107817307B (zh) * 2017-11-01 2020-12-25 重庆华邦制药有限公司 Hplc法分离测定帕司烟肼及其相关杂质的方法
WO2019145174A1 (en) 2018-01-23 2019-08-01 Basf Se Preparation of optionally substituted 5-substituted pyridine
CN111630033A (zh) 2018-01-23 2020-09-04 巴斯夫欧洲公司 任选取代的二氢异喹啉的制备
US11591312B2 (en) 2018-01-23 2023-02-28 Basf Se Halogenation of pyridine derivatives
WO2019145177A1 (en) 2018-01-23 2019-08-01 Basf Se Bromination of pyridine derivatives
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
TWI803696B (zh) * 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
WO2020104930A1 (en) * 2018-11-20 2020-05-28 Piramal Enterprises Limited An improved asymmetric synthesis of azaspiro compounds
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
KR20220082804A (ko) * 2019-07-17 2022-06-17 싸이토키네틱스, 인코포레이티드 심장 근섬유분절 억제제 경구 제제들
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物
JP2021123539A (ja) * 2020-02-03 2021-08-30 キッセイ薬品工業株式会社 ピロロピリミジノン化合物
EP4219500A4 (en) 2020-04-14 2024-10-23 Nissan Chemical Corporation FUSED HETEROCYCLIC COMPOUND
CN111393366B (zh) * 2020-06-05 2020-09-01 北京华氏开元医药科技有限公司 四氢异喹啉类衍生物、制备方法、药物组合物及应用
EP4185381A4 (en) * 2020-07-24 2024-08-21 Inipharm, Inc. Thiophene hsd17b13 inhibitors and uses thereof
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AU2021377248A1 (en) 2020-11-13 2023-06-22 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
CN113072420B (zh) * 2021-02-23 2022-05-20 中山大学 一类2-芳基取代的偕二氟环丁烷类化合物及其制备方法
CN116490498B (zh) * 2021-03-19 2025-09-02 南京迈晟科技有限责任公司 嘧啶并环类化合物及其用于制备治疗疼痛、脊髓损伤药物中的用途
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物
CA3246424A1 (en) 2022-04-08 2023-10-12 SHY Therapeutics LLC Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2024109788A1 (zh) * 2022-11-23 2024-05-30 成都先导药物开发股份有限公司 Parp7抑制剂及其制备方法和用途
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法
WO2025006293A2 (en) * 2023-06-26 2025-01-02 Merck Sharp & Dohme Llc Inhibitors of human respiratory syncytial virus and metapneumovirus

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040047A (en) 1960-04-04 1962-06-19 Takeda Pharmaceutical 2-(pyrazol-1-yl)-pyrimidine derivatives
JPH04182636A (ja) 1990-11-19 1992-06-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
JPH05341428A (ja) 1992-06-10 1993-12-24 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
TW312694B (enExample) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
CA2373510A1 (en) 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
KR100929513B1 (ko) * 2001-12-13 2009-12-03 아스비오파마 가부시키가이샤 Ｐｄｅ７ 저해 작용을 갖는 피라졸로피리미디논 유도체
GB2388594A (en) * 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
NZ544756A (en) 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1696877A4 (en) 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
AU2005288858B2 (en) 2004-09-30 2011-04-21 Janssen R&D Ireland HCV inhibiting bi-cyclic pyrimidines
BRPI0608411A2 (pt) 2005-03-10 2009-12-29 Basf Ag uso de um composto, composto, processo para preparar compostos, agente, semente, e, processo para combater fungos nocivos fitopatogênicos
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
EP1921067A1 (en) 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
WO2008055709A1 (en) 2006-11-08 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti -inflammatory agents
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
ATE542799T1 (de) 2007-03-08 2012-02-15 Janssen Pharmaceutica Nv Chinolinonderivate als parp und tank-inhibitoren
WO2008131050A1 (en) 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20110046137A1 (en) 2007-05-10 2011-02-24 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
JP2010533736A (ja) * 2007-07-19 2010-10-28 ハー・ルンドベック・アクチエゼルスカベット ５員複素環アミドおよび関連化合物
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
ES2548250T3 (es) 2009-02-10 2015-10-15 Janssen Pharmaceutica, N.V. Quinazolinonas como inhibidores de prolilhidroxilasa
US20120252791A1 (en) 2009-09-17 2012-10-04 Julian Blagg Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain
EP2488025A4 (en) * 2009-10-15 2013-04-03 Childrens Medical Center SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
WO2011088045A1 (en) 2010-01-12 2011-07-21 Ambit Biosciences Corporation Aurora kinase compounds and methods of their use
WO2011138142A1 (en) 2010-05-07 2011-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and use of sulfasalazine
DK2822656T3 (en) * 2012-03-07 2017-01-30 Inst Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
JP6097820B2 (ja) 2012-05-04 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピロロトリアジノン誘導体
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
AR097631A1 (es) * 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos

Also Published As

Publication number Publication date
DK3356345T3 (da) 2024-02-12
EP3356345A1 (en) 2018-08-08
EP3356345B1 (en) 2023-11-08
WO2017059191A1 (en) 2017-04-06
CA3038280A1 (en) 2017-04-06
US9963462B2 (en) 2018-05-08
JP2018529739A (ja) 2018-10-11
US20170096435A1 (en) 2017-04-06
ES2969565T3 (es) 2024-12-13

Similar Documents

Publication Publication Date Title
JP6896715B2 (ja) セピアプテリン還元酵素としてのヘテロアリール誘導体
AU2020220079B2 (en) Heterocyclic compounds as RET kinase inhibitors
US11661423B2 (en) Heterocyclic compounds as RET kinase inhibitors
TWI478924B (zh) 咪唑并嘧啶衍生物
KR101548443B1 (ko) 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
AU2009259209B2 (en) Novel phenylimidazole derivatives as PDE10A enzyme inhibitors
CN102971317B (zh) 四氢-吡啶并-嘧啶衍生物
US20100016279A1 (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
KR102039764B1 (ko) 신규 티에노피리미딘 유도체, 그의 제조 방법 및 그의 치료 용도
JP2010535189A (ja) ピラゾール化合物およびＲａｆ阻害剤としてのその使用
AU2013322838A1 (en) New bicyclic derivatives
CN102753551A (zh) 作为pde10a酶抑制剂的2-芳基咪唑衍生物
MX2013006054A (es) Compuestos de triazolopiridina.
CN117917405A (zh) Kif18a蛋白抑制剂
CN116888126A (zh) 一种酪蛋白激酶抑制剂的化合物
CA2602303A1 (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
JP7611900B2 (ja) 縮合複素環化合物
WO2023116865A1 (zh) 含吡唑类衍生物、其药学上可接受的盐及其制备方法和应用
Meniconi Heteroaryl derivatives as sepiapterin reductase inhibitors
AU2023320651A1 (en) TGF-β INHIBITOR COMPOUND AND USE THEREOF
WO2025026745A1 (en) Parp1 inhibitor compounds
JP6471169B2 (ja) 神経学的障害の処置のための（ヘテロ）アリールイミダゾール類／ピラゾール類
NZ787350A (en) Heterocyclic compounds as ret kinase inhibitors
NZ786565A (en) Heterocyclic compounds as ret kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210421

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210609

R150 Certificate of patent or registration of utility model

Ref document number: 6896715

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250